The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
本发明涉及化合物和方法,用于作为磷酸二酯酶4(PDE4)的抑制剂,用于治疗或预防疾病。
Heteroaryl inhibitors of PDE4
申请人:Tetra Discovery Partners, LLC
公开号:US09221843B2
公开(公告)日:2015-12-29
The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.
本发明涉及化合物和方法,用于作为磷酸二酯酶4(PDE4)的抑制剂,用于治疗或预防疾病。
Discovery of triazines as selective PDE4B versus PDE4D inhibitors
作者:Timothy J. Hagen、Xuesheng Mo、Alex B. Burgin、David Fox、Zheng Zhang、Mark E. Gurney
DOI:10.1016/j.bmcl.2014.06.002
日期:2014.8
In this study we report a series of triazine derivatives that are potent inhibitors of PDE4B. We also provide a series of structure activity relationships that demonstrate the triazine core can be used to generate subtype selective inhibitors of PDE4B versus PDE4D. A high resolution co-crystal structure shows that the inhibitors interact with a C-terminal regulatory helix (CR3) locking the enzyme in an inactive 'closed' conformation. The results show that the compounds interact with both catalytic domain and CR3 residues. This provides the first structure-based approach to engineer PDE4B-selective inhibitors. (C) 2014 Elsevier Ltd. All rights reserved.